comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 19:26:41 - browse：3185

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Patients, digital health players weigh in on FTC's data privacy plan

WSS

White House calls on federal agencies to crack down on AI abuses

Medicare will require more price transparency from hospitals

Victims of gun violence feel impacts long after bullet wound

Megan Rapinoe shares emotional post following US Women's World Cup exit

The new shift in health care is toward less care

Novo Nordisk touts Wegovy study, but still struggling with supply

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

White House calls on federal agencies to crack down on AI abuses

Walensky prepares to leave CDC — and Congress — behind

STAT Executive Editor Rick Berke on STAT's 8th birthday

Tori Bowie and the unacceptable rates of Black maternal death

A clever new way to fix Medicaid and graduate medical education

Jerome Adams on the need for new antivirals for Covid

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UCSF medical school apologizes for unethical prisoner experiments

Wikipedia

Removing probiotics from the NICU could threaten preemies' health

More doctors should go into startup world

After Optum profits sink, UnitedHealth makes changes

Montana youths win climate lawsuit against state for promoting fossil fuels

Senators push IRS to launch nonprofit hospital probe

Bird flu researchers hone in on Finland’s mink farms

leisure time

focus

Wikipedia

hotspot